Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Jazz Jumps On Defibrotide Priority Review

This article was originally published in Scrip

Executive Summary

Shares of Jazz Pharmaceuticals plc jumped 8% in morning trading on Sept. 30 on word the FDA had granted a priority review of the company's new drug application (NDA) for its anticoagulant defibrotide as a treatment for patients with hepatic veno-occlusive disease (VOD) with evidence of multi-organ dysfunction (MOD) following hematopoietic stem-cell transplantation (HSCT).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register